Patents by Inventor Rajashree Joshi-Hangal
Rajashree Joshi-Hangal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
PHARMACEUTICAL FORMULATIONS COMPRISING SALTS OF A PROTEIN KINASE INHIBITOR AND METHODS OF USING SAME
Publication number: 20110086112Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.Type: ApplicationFiled: October 18, 2010Publication date: April 14, 2011Applicant: SUPERGEN, INC.Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati -
Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
Patent number: 7820684Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.Type: GrantFiled: March 3, 2008Date of Patent: October 26, 2010Assignee: SuperGen, Inc.Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati -
PHARMACEUTICAL FORMULATIONS COMPRISING SALTS OF A PROTEIN KINASE INHIBITOR AND METHODS OF USING SAME
Publication number: 20080226747Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.Type: ApplicationFiled: March 3, 2008Publication date: September 18, 2008Applicant: SUPERGEN, INC.Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati -
Patent number: 7144873Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: GrantFiled: July 13, 2004Date of Patent: December 5, 2006Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Patent number: 7135464Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: GrantFiled: July 13, 2004Date of Patent: November 14, 2006Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Publication number: 20060128653Abstract: The present invention provides pharmaceutical formulations of decitabine or 5-aza-2?-deoxycytidine as well as methods of manufacturing the formulations. In particular, decitabine is formulated with a cyclodextrin compound to stabilize and/or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering decitabine to treat conditions or diseases, such as cancer and hematological disorders.Type: ApplicationFiled: December 10, 2004Publication date: June 15, 2006Inventors: Chunlin Tang, Rajashree Joshi-Hangal
-
Publication number: 20060128654Abstract: The present invention provides pharmaceutical formulations of cytidine analogs and derivatives, such as 5-azacytidine, 5-aza-2?-deoxy-2?,2?-difluorocytidine, 5-aza-2?-deoxy-2?-fluorocytidine, 2?-deoxy-2?,2?-difluorocytidine, and cytosine 1-?-D-arabinofuranoside, as well as methods of manufacturing the formulations. In particular, the cytidine analog or derivative is formulated with a cyclodextrin compound to stabilize and/or enhance solubility of the drug. Kits and methods for using the pharmaceutical formulations are also provided, including methods of administering the cytidine analog or derivative to treat conditions or diseases, such as cancer and hematological disorders.Type: ApplicationFiled: December 10, 2004Publication date: June 15, 2006Inventors: Chunlin Tang, Rajashree Joshi-Hangal
-
Publication number: 20060014949Abstract: Pharmaceutical compositions and methods for treatment of neoplastic conditions using polymorphs of decitabine are provided. Also provided are methods for manufacturing and administering such pharmaceutical compositions.Type: ApplicationFiled: July 13, 2004Publication date: January 19, 2006Applicant: SuperGen Inc.Inventors: Sanjeev Redkar, Rajashree Joshi-Hangal
-
Patent number: 6982253Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: GrantFiled: June 5, 2002Date of Patent: January 3, 2006Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Publication number: 20040259820Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: ApplicationFiled: July 13, 2004Publication date: December 23, 2004Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Publication number: 20040259821Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: ApplicationFiled: July 13, 2004Publication date: December 23, 2004Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Patent number: 6828346Abstract: Methods are provided for using paclitaxel for treating diseases associated with abnormal cell proliferation and angiogenesis. In particular, methods are provided for administration of paclitaxel formulated with vitamin E derivatives such as d-&agr;-tocopherol polyethylene glycol succinate to a cancer patient. By administering to a patient paclitaxel in a vehicle containing a solubilizer other than Cremophor, acute hypersensitivity caused by Cremophor can be avoided and therapeutic index of paclitaxel may also be increased through potentiation of anti-neoplastic effects by the vitamin E derivatives.Type: GrantFiled: January 23, 2003Date of Patent: December 7, 2004Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Howard Sands, Joseph Rubinfeld
-
Publication number: 20040167205Abstract: A method is provided for preparing a pharmaceutical composition comprising: taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen for a period of time, the exposure to the gas over the period of time causing an acidity of the polyoxyethylated castor oil to increase; and forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil and a pharmaceutically active agent such as paclitaxel; wherein at least 80% of the potency of the pharmaceutically active agent is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.Type: ApplicationFiled: February 18, 2004Publication date: August 26, 2004Applicant: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Joseph Rubinfeld, Sanjeev Redkar, Ashok Y. Gore
-
Patent number: 6710195Abstract: A method is provided for preparing a pharmaceutical composition comprising: taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen for a period of time, the exposure to the gas over the period of time causing an acidity of the polyoxyethylated castor oil to increase; and forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil and a pharmaceutically active agent such as paclitaxel; wherein at least 80% of the potency of the pharmaceutically active agent is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.Type: GrantFiled: November 26, 2002Date of Patent: March 23, 2004Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Joseph Rubinfeld, Sanjeev Redkar, Ashok Y. Gore
-
Publication number: 20030229047Abstract: Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.Type: ApplicationFiled: June 5, 2002Publication date: December 11, 2003Inventors: Rajashree Joshi-Hangal, Xichen Zhang, Stephanie Gong, Sanjeev Redkar, Ashok Y. Gore
-
Publication number: 20030191179Abstract: Methods are provided for using paclitaxel for treating diseases associated with abnormal cell proliferation and angiogenesis. In particular, methods are provided for administration of paclitaxel formulated with vitamin E derivatives such as d-&agr;-tocopherol polyethylene glycol succinate to a cancer patient. By administering to a patient paclitaxel in a vehicle containing a solubilizer other than Cremophor, acute hypersensitivity caused by Cremophor can be avoided and therapeutic index of paclitaxel may also be increased through potentiation of anti-neoplastic effects by the vitamin E derivatives.Type: ApplicationFiled: January 23, 2003Publication date: October 9, 2003Applicant: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Howard Sands, Joseph Rubinfeld
-
Publication number: 20030153614Abstract: A method is provided for preparing a pharmaceutical composition comprising: taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen for a period of time, the exposure to the gas over the period of time causing an acidity of the polyoxyethylated castor oil to increase; and forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil and a pharmaceutically active agent such as paclitaxel; wherein at least 80% of the potency of the pharmaceutically active agent is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.Type: ApplicationFiled: November 26, 2002Publication date: August 14, 2003Inventors: Rajashree Joshi-Hangal, Joseph Rubinfeld, Sanjeev Redkar, Ashok Y. Gore
-
Patent number: 6538020Abstract: A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: paclitaxel, a water-miscible amide and a pharmaceutically-acceptable, water-miscible solubilizer selected from the group consisting of solubilizers having the general structures R1COOR2, R1CONR2, and R1COR2, wherein R1 is a hydrophobic C3-C50 alkane, alkene or alkyne and R2 is a hydrophilic moiety.Type: GrantFiled: September 5, 2001Date of Patent: March 25, 2003Assignee: Super Gen, Inc.Inventors: Rajashree Joshi-Hangal, Ashok Y. Gore, Joseph Rubinfeld, Rajesh Shrotriya
-
Patent number: 6509370Abstract: A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharmaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structures R1COOR2, R1CONR2, and R1COR2, wherein R1 is a hydrophobic C3-C50 alkane, alkene or alkyne and R2 is a hydrophilic moiety. The solubilizer is selected such that it does not have a pKa less than about 6.Type: GrantFiled: July 9, 2002Date of Patent: January 21, 2003Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Ashok Y. Gore, Joseph Rubinfeld, Rajesh Shrotriya
-
Publication number: 20020103254Abstract: A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: paclitaxel, a water-miscible amide and a pharmaceutically-acceptable, water-miscible solubilizer selected from the group consisting of solubilizers having the general structuresType: ApplicationFiled: September 5, 2001Publication date: August 1, 2002Inventors: Rajashree Joshi-Hangal, Ashok Y. Gore, Joseph Rubinfeld, Rajesh Shrotriya